Parafibromin is a protein product derived from the hyperparathyroidism 2(HRPT2) tumor suppressor gene and its inactivation has been coupled to familial and sporadic forms of parathyroid malignancy. In this study, we have conducted immunohistochemistry on 33 parathyroid carcinomas (22 unequivocal and 11 equivocal) using four parafibromin antibodies directed to different parts of the protein.
Introduction
Parathyroid carcinoma is an uncommon but potentially life-threatening form of primary hyperparathyroidism (PHPT; Grimelius & Johansson 1997 , Shane 2001 , Rodgers & Perrier 2006 . The patients can develop a palpable mass in the neck, concomitant kidney, and bone disease, and frequently high parathyroid hormone (PTH) levels along with persistent hypercalcemia in the case of locally invasive or metastatic disease (Mittendorf & McHenry 2005) . Early detection and en bloc resection of all tumor tissue is necessary for a favorable outcome (Rodgers & Perrier 2006) . However, parathyroid carcinoma often presents a diagnostic challenge both concerning presurgical distinction between a highly active adenoma and the malignant counterpart, as well as histopathological identification of carcinoma in the absence of invasive growth pattern (Sandelin et al. 1992 , DeLellis 2005 . While unequivocal parathyroid carcinoma shows indisputable evidence of malignancy such as invasion, metastasis, or recurrence (DeLellis et al. 2004) , equivocal cancers only present characteristics associated with malignant behavior at histopathology (Bondeson et al. 1993) . The difficulties in parathyroid tumor diagnosis are further exemplified by the histological subgroup 'atypical adenoma' which is considered of uncertain malignant potential (Levin et al. 1987) . In the search of a marker for parathyroid malignancy, analysis of DNA content, and immunohistochemical expression of pRb, bcl-2, Ki-67, cyclin D1, p21, and p53 have been evaluated, but not found to be specific enough (Bondeson et al. 1993 , Cryns et al. 1994 , Erickson et al. 1999 , Farnebo et al. 1999 , Vasef et al. 1999 , Stojadinovic et al. 2003 . The hyperparathyroidism 2 (HRPT2) gene is the disease gene for hyperparathyroidism-jaw tumor syndrome (HPT-JT), characterized by benign and malignant PHPT in combination with tumors of the jaws, kidney, and uterus (Carpten et al. 2002 , Bradley et al. 2005 . Its encoded protein parafibromin is a member of the polymerase-associated factor 1 (PAF1) complex associated with RNA polymerase II which regulates transcription elongation and histone modification (Carpten et al. 2002 , Rozenblatt-Rosen et al. 2005 , Yart et al. 2005 . In vitro studies have revealed dominant negative tumor suppressor properties (Zhang et al. 2006) , a functional nuclear localization signal (NLS; Hahn & Marsh 2005 , Woodard et al. 2005 , Zhang et al. 2006 , Bradley et al. 2007 , and coupling to the wingless type (Wnt) signaling pathway (Mosimann et al. 2006) .
Inactivating HRPT2 mutations are frequently detected on the somatic and sometimes germ line levels in apparently sporadic parathyroid carcinoma (Howell et al. 2003 , Shattuck et al. 2003 , Cetani et al. 2004 , as opposed to a small minority of adenomas (Carpten et al. 2002 , Howell et al. 2003 , Krebs et al. 2005 , Bradley et al. 2006 , Juhlin et al. 2006 . In immunohistochemical studies of unequivocal and HPT-JT-related carcinomas, complete loss, or reduced nuclear immunoreactivity was found in the majority of cases. By contrast, 98-100% of unselected sporadic adenomas stained completely positive (Tan et al. 2004 , Gill et al. 2006 . In a subset of cystic adenomas, loss of parafibromin has been associated with HRPT2 mutations (Juhlin et al. 2006) .
Here, we have evaluated immunohistochemical expression of parafibromin in parathyroid carcinomas using antibodies directed to different epitopes of the protein and further related the findings to western blot analyses and genetic information.
Materials and methods

Parathyroid carcinoma patients and tissue samples
This study includes 33 tumor samples collected worldwide from 32 patients (Table 1) . Twenty-four samples are part of a previously published historical material (Bondeson et al. 1993 , Farnebo et al. 1999 . Six cases carry inactivating HRPT2 mutations, five of which have been previously reported (Shattuck et al. 2003) . Three additional samples were newly collected with informed consent and ethical approval from two patients undergoing surgery at Karolinska University Hospital in Stockholm.
Histopathological classifications of tumor specimens were according to the WHO criteria. Twentytwo patients had definite (unequivocal) cancer with vascular invasion, and/or local invasion of surrounding organs, and/or distant metastasis, and/or evidence of recurrence after parathyroid surgery. They also exhibited tumor characteristics associated with parathyroid cancer such as fibrous bands, mitotic figures, focal necrosis, macronucleoli, and distinct cellular atypia (T1-T22, Table 1 ). The 11 cases classified as equivocal carcinomas exhibited at least one histopathological indication of malignancy mentioned above, but were without evidence of recurrence, invasion, or metastases (T23-T33, Table 1 ). Sample T13 was originally classified as an adenoma; however, this tumor relapsed 4 years after primary surgery thereby establishing the diagnosis as unequivocal carcinoma in this patient.
Control samples
The following positive controls were used: HeLa cells transfected with plasmid DNA containing full-length HRPT2 cDNA and two parathyroid carcinomas (T4 and T23) for western blot and immunohistochemistry (Juhlin et al. 2006) , four paraffin-embedded adenomas on the same slide for immunohistochemistry including one with a rim of normal parathyroid (control adenoma 1) and 21 sporadic adenomas (the majority with a normal rim) as normal reference for immunohistochemistry. For sub-cellular fractionation and western blot analysis, frozen samples of two cystic adenomas with or without HRPT2 gene mutation and parafibromin inactivation (corresponding to T20 and T23 in Juhlin et al. 2006) , one secondary HPT gland, and a regular adenoma (control adenoma 2) were used. All samples were obtained with informed consent and local ethical approval.
Antibodies and blocking peptides
A rabbit polyclonal antibody TNYV was raised with ethical approval against aa 39-58 by the authors through AgriSera Co. (Umeå, Sweden) using published methodology (Polak & Van Noorden 1986) , affinity purified and eluated at pH 7.0. The mouse monoclonal antibody 2H1 targets aa 87-100 (Santa Cruz Biotechnology, Santa Cruz, CA, USA). BL648 is an affinity-purified rabbit polyclonal antibody directed against a 24 aa sequence within aa 250-300 (Bethyl Laboratories, Montgomery, TX, USA). APVF, an Case T16 and T33 was originally described as 'walnut' and 'hazelnut' respectively.
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Western blot analyses
Total proteins were extracted according to standard procedures, quantified using a dye-binding assay (Bradford 1976) , and used for western blot analyses using previously described methodology (Juhlin et al. 2006) . The sub-cellular fractionation and verification with anti Lamin A/C and anti Prohibitin was performed as previously described or has been reported before (Forsberg et al. 2006) . After electrophoresis and blotting, presence of protein was confirmed by staining with Ponceau Red solution (Sigma-Aldrich), and the membranes were incubated with the respective parafibromin antibody: 1.7 mg/ml TNYV (1:300), 4 mg/ml 2H1 (1:50), 0.2 mg/ml BL648 (1:5000), 1.7 mg/ml APVF (1:300), followed by the respective secondary HRP-conjugated antibody (goat anti-rabbit 1:12 500, goat anti-mouse 1:10 000 Bio-Rad Laboratories). In control experiments, the antibodies were preincubated with peptide antigen for 1 h at room temperature and 2 h at 4 8C.
Immunohistochemistry
Paraffin sections of parathyroid carcinomas and control samples were cut at 4 mm, deparaffinized, rehydrated, and immersed in preheated citrate buffer pH 6 (Dako, Glostrup, Denmark) at 95 8C for 20 min. In our experience, antigen retrieval by heating in citrate buffer was necessary to obtain a distinct nuclear signal without interfering background, in agreement with previous publications (Tan et al. 2004 , Gill et al. 2006 . For the monoclonal antibody 2H1, the following parameters were tested: antibody dilution (1:20, 1:100, and 1:200), antigen retrieval time (10, 20, 30, and 50 min) as well as incubation time (1 h and overnight). These parameters were studied in four adenomas on the same slide and in carcinomas T4, T14, T15, and T23. In our laboratory settings, we obtained expected positive immunoreactivity in the adenomas and the western blot verified carcinomas using citrate heating for 20 min, antibody dilution of 1:20, and overnight incubation. Positive signals were not obtained using shorter antigen retrieval time, increased antibody dilution, or shorter incubation time.
The sections were incubated in 0.3% hydrogen peroxide in water for 30 min, blocked in 1% BSA with 0.01% sodium azide for 45 min, and incubated with primary antibody diluted in 1% BSA overnight using concentrations determined from dilution trials with positive controls: TNYV 2 mg/ml (1:250), 2H1 10 mg/ml (1:20), BL648 10 mg/ml (1:100), and APVF 2 mg/ml (1:250). The slides were then incubated with biotinylated secondary antibody (7.5 mg/ml (1:100) of goat anti-rabbit BA-1000 and horse anti-mouse B-200; Vector Laboratories, Burlingame, CA, USA) for 45 min, and the antigen-antibody complex was visualized using the avidin-biotin-peroxidase complex method (Vectastain Elite Kit, Vector Laboratories) for 45 min, followed by diaminobenzidine tetrahydrochloride for 6 min, and counterstaining in hematoxylin for 3 min. Sections were washed in five cycles of Tris-buffered saline (TBS, pH 7.6) between each step. Peptide neutralization tests for all four parafibromin antibodies were performed on all cases as negative controls.
Parafibromin expression was independently scored by two of the authors (C J and A H), whereby the levels of expression and the sub-cellular localization were evaluated. Each specimen was classified as having either 'negative' (staining of %10% tumor nuclei), 'partial loss' (staining of 11-89% of tumor nuclei), or 'positive' (staining of R90% of tumor nuclei) parafibromin expression. The partial loss group was further studied by scoring at least 1500 cells from a total offive randomly selected grid areas of the sections in high power magnification (40!). The cells were classified as having either positive or negative nuclear parafibromin expression. The negative controls were independently evaluated by three of the authors (C J, F H, and A H), including an author blinded of the primary positive findings. All slides were blinded of their diagnosis during the entire microscopic validation process.
Results
Antibody characterization and western blot analysis
The four parafibromin antibodies gave similar results with high affinity for a w60 kDa band representing the predicted size of parafibromin (Figs 1 and 2) . Furthermore blocking experiments with corresponding immunizing peptides confirmed the specificity of our findings. Strong expression was revealed in HRPT2-transfected HeLa cells, when compared with the weaker endogenous signal observed in untransfected HeLa cell controls (Fig. 2) . The secondary HPT gland showed positive parafibromin expression in the total and nuclear extracts, while in the cytosolic extract parafibromin was absent or showed weak expression (Fig. 2) . Similar results were obtained at analysis of nuclear and cytosolic extracts from control adenoma 2 (Fig. 3B ). In the cystic adenoma with wild-type HRPT2 (Juhlin et al. 2006) , all four antibodies detected a w60 kDa product (Fig. 2) , while the cystic adenoma with known HRPT2 mutation (Juhlin et al. 2006 ) was negative for parafibromin by means of all four antibodies used (Fig. 2) . 
Immunohistochemical analysis of parafibromin expression
In control experiments, HRPT2-tranfected HeLa cells, the four regular parathyroid adenomas and normal parathyroid tissue (control adenoma 1) showed strong nuclear expression of parafibromin for each of the parafibromin antibodies, whereas the cytoplasm was only weakly positive in these samples (Fig. 3A) . In addition, 21 sporadic adenomas analyzed with 2H1 showed positive expression in all cases (data not shown).
Examples of tumors scored as having negative, partial loss, or positive parafibromin expression are shown in Fig. 4 . Fourteen of the 22 unequivocal carcinoma samples (64%) demonstrated partial loss of parafibromin expression with 25-83% positive nuclei, and one sample (4%) was completely negative for parafibromin immunoreactivity (T5, Table 2, Fig. 4) . The remaining seven samples (32%) were positive, exhibiting parafibromin expression in almost 100% of the tumor cell nuclei. Among the equivocal carcinomas, 5 out of 11 cases (45%) exhibited partial loss, ranging from 52 to 80% positive nuclei (Table 2) , while six samples (55%) were completely positive for parafibromin nuclear expression. Samples T4 and T7, representing two relapses within 1-year time in the same patient, were both completely positive.
In general, positive samples demonstrated nuclear staining, while surrounding fibrous tissue was negative. Accompanying low levels of cytoplasmic staining were often observed at varying levels between tumors, especially with the BL648 antibody. In support of the specificity of the nuclear and cytoplasmic signals, the positive expression was completely eliminated in the subsequent blocking experiments.
The immunohistochemical findings were also supported by western blot analysis of two positive carcinomas (Fig. 2) . Sample T4 represents a relapsing unequivocal carcinoma growing into the larynx, esophagus, and blood vessels, and sample T23 is an equivocal carcinoma from a 16-year-old boy. Both these tumors expressed the w60 kDa product at western blot analyses.
Discussion
The concordant results obtained at immunohistochemistry and western blot analyses suggest that the four antibodies are adequate in detecting parafibromin regarding both sensitivity and specificity. Moreover, the predominant nuclear localization observed at immunohistochemistry and sub-cellular fractionation is in accordance with previous reports ( Optimal methodological conditions for parafibromin immunohistochemistry are crucial if the results ought to be used for diagnostic purposes. We found that the results were influenced by the intensity of antigen retrieval, antibody dilution, and incubation time. The combination of immunohistochemistry and western blot analysis was, as illustrated in case T4 and T23, used to adjust the immunohistochemical methodology to positive findings in these parathyroid carcinomas evidently expressing parafibromin demonstrated by western blot analysis.
Partial loss of parafibromin immunoreactivity was frequently detected, while negative staining was only observed in a single carcinoma. Similar results were obtained for the four antibodies used with comparable proportions of positive and negative cells in individual cases. The concordant findings with the different antibodies would suggest that full-length parafibromin is present in the positive nuclei found. Furthermore, the positive findings with BL648 and APVF would suggest that the functionally important b-catenin interaction domain (CID) and complex-binding domain (Cdc73) domains are physically present in the positive nuclei found.
Two tumors with double somatic HRPT2 mutations exhibited positive and partial loss of parafibromin expression respectively. This situation is not generally expected in the case of tumor suppressor gene inactivation, where loss of the normal function often is seen. However, a previous study has demonstrated in vitro expression of truncated parafibromin protein resulting from site-specific HRPT2 mutations introduced in a cell line, suggesting that HRPT2 mutated cells can still propel the production of parafibromin, albeit structurally defective (Zhang et al. 2006) . In our two cases with double mutations, this finding offers a possible explanation for the positive results obtained with the three most N-terminally located parafibromin antibodies. Furthermore, both tumors with double HRPT2 mutations carry one deleterious mutation in exon 8 (Table 1 ). The resulting frameshifts fortuitously creates new amino acid sequences prior to truncation that have partial homology with the APVF immunizing peptide; thus cross-binding with the APVF polyclonal antibody (although affinity purified) cannot be excluded. In general, the complexity of parafibromin immunostaining might be aggravated by other factors. For example, increased proliferation can result from co-expression of mutant and wild-type parafibromin (Zhang et al. 2006) . Furthermore, parathyroid carcinomas reveal frequent gain of 1q, including the HRPT2 gene locus (Kytölä et al. 2000) , in contrast to the frequent observations of copy number losses at other tumor suppressor gene loci such as the MEN1 locus in parathyroid adenomas. The present study agrees with previous reports in which normal parathyroid tissue and parathyroid adenomas show positive parafibromin expression in all cells, giving a high specificity for the method. Since adenomas in turn are much more frequent than carcinomas, the negative predictive value (i.e. the chance that an adenoma is correctly identified by positive parafibromin staining) would end up as high, although probably not 100% since reduced expression of parafibromin has been reported in small subsets of parathyroid adenomas (Gill et al. 2006 , Juhlin et al. 2006 . Hence, in parathyroid tumors with positive parafibromin expression, the risk of malignancy is very low, however, cannot be fully excluded. In the group with partial loss or negative staining, a putative positive predictive value (i.e. the chance that a carcinoma is correctly identified by negative parafibromin staining) would end up as low, indicating that a negative staining is not automatically consistent with parathyroid carcinoma. Cases with partial loss or negative staining could either be parathyroid carcinomas or adenomas likely carrying an HRPT2 mutation. In this group, mutation screening of tumor and blood is well motivated especially for detection of familial disease.
The question arises whether tumors diagnosed as parathyroid adenomas with partial loss or negative parafibromin staining could have a more aggressive course of disease. One tumor in our series exemplifies this situation; sample T13 was originally classified as an adenoma; however, the advent of recurrent disease 4 years after primary surgery ascertained this tumor as carcinoma. Careful histopathological reexamination of the primary lesion found no evidence for malignant disease, although our ensuing parafibromin staining of this specimen was consistent with partial loss. Further analysis of similar cases will establish whether parafibromin immunostaining could detect malignant potential before the occurrence of required histopathological characteristics.
The initial findings of frequent HRPT2 mutations in parathyroid carcinomas have inspired the development of parafibromin antibodies for immunohistochemical applications. The presently available data suggest that this approach has additive value in parathyroid diagnostics. However, loss of parafibromin immunoreactivity cannot be used as a diagnostic marker alone since the sensitivity is limited. Mutation screening of HRPT2 is expected to increase the sensitivity as illustrated in this study where three of the six cases with known HRPT2 mutations had positive expression (100% positive nuclei). Additional biomarkers for identification of parathyroid malignancy before the development of spread disease could be sought among markers for high proliferation and within the parafibromin pathways.
To summarize, parafibromin immunohistochemistry could be applied as an additional diagnostic marker. Positive expression would indicate benign disease, however, does not fully exclude a cancer diagnosis or the presence of an HRPT2 mutation. Negative or partial loss staining of parafibromin should motivate genetic analysis of the HRPT2 gene in blood and tumor tissue from the affected patient. However, our results suggest that parafibromin immunostaining cannot replace genetic testing or be used as a sole discriminator to separate adenoma from carcinoma. Our findings furthermore suggest that there exists no 'epitope of choice' for parafibromin detection related to malignant behavior of parathyroid tumors.
